2026 NPPES data Dermatology Physician NPI 1245368695 M.D.
Verify on CMS →

MATHEW CANNAVA, M.D.

Dermatology Physician in SOLDOTNA, Alaska. CMS National Plan and Provider Enumeration System profile including specialty classification, practice address, and Medicare prescribing data when reported.

Federal data — no proprietary rating. PlainDoctor publishes the actual CMS NPPES and Medicare records — NPI registration, specialty, practice location, and prescribing data — without a composite score or editorial opinion on top. Every field traces to a federal source.
Prescribing volume
456
Medicare Part D claims · 247 beneficiaries · Dermatology Physician avg: 729
Generic prescribing
93%
generic claims · 7% brand-name · higher generic rates reduce patient out-of-pocket costs
MIPS score
0/100
▼ 83 pts below national avg 83.1 · [object Object]

What the federal data shows

MATHEW CANNAVA, M.D. reported a CMS MIPS final score of 0/100 — below the 83.1 national average — and filed 456 Medicare Part D claims in 2023.

0/100
MIPS score · -83 vs avg
456
Part D claims, 2023
93%
generic prescribing
Likely
board-certified (heuristic)

Every figure on this page comes straight from federal CMS records (NPPES, Medicare Part D, MIPS, Open Payments) — no proprietary rating or editorial opinion is applied.

MATHEW CANNAVA, M.D.'s MIPS score vs every scored U.S. clinician

CMS Merit-based Incentive Payment System (MIPS) final score, 2023 — the federal quality measure

0 0th percentile higher than 0% of 477,587 scored providers

0–10: 8,684 scored providers (2%). This entry sits in this band. 10–20: 3,008 scored providers (1%). Above this entry. 20–30: 3,069 scored providers (1%). Above this entry. 30–40: 2,746 scored providers (1%). Above this entry. 40–50: 2,928 scored providers (1%). Above this entry. 50–60: 5,882 scored providers (1%). Above this entry. 60–70: 13,906 scored providers (3%). Above this entry. 70–80: 118,074 scored providers (25%). Above this entry. 80–90: 129,887 scored providers (27%). Above this entry. 90–100: 189,403 scored providers (40%). Above this entry. This provider 0 100 every MIPS-scored clinician, bucketed by value

Each bar is a band; taller bars hold more scored providers. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source CMS Merit-based Incentive Payment System (MIPS) · 2023

Board certification likely (heuristic — not verified)

MATHEW CANNAVA, M.D. practices in an ABMS-board-eligible specialty and shows active CMS Medicare participation + MIPS quality reporting — signals consistent with board-certified status. For verified board certification, see CertificationMatters.org (the official ABMS public lookup).

What does the federal data show about MATHEW CANNAVA, M.D.?

Below national average

NPI registry status

Active

Issued 02/28/2007

NPI 1245368695

Primary specialty

Dermatology Physician

Mid-sized

14,610 US NPIs in this specialty

Medicare Part D claims

456 37% vs specialty avg

2023 prescription claims

Specialty avg: 729

MIPS final score

0/100 83.1% pts

Penalty band band

vs 83.1 national avg

Specialty distribution in Alaska

How Dermatology Physician compares to other specialties among Alaska providers

Alaska providers

Dermatology Physician share within Alaska

1. Dermatology Physician42%2. Internal medicine21%3. Family medicine17%4. Surgical12%5. Pediatric8%
Dermatology Physician share within Alaska

Medicare quality performance — MIPS

MATHEW CANNAVA, M.D.'s 2023 MIPS final score plotted against the Dermatology Physician national average

Below national average
MIPS Final Score
0/100
vs 83.1 national avg · 2023 performance year

MIPS final score (Dermatology Physician) — 0/100 vs national avg 83.1

0%100%National avg83%0%
MIPS final score (Dermatology Physician) — 0/100 vs national avg 83.1

The Merit-based Incentive Payment System (MIPS) scores providers 0–100 across four performance categories: Quality, Cost, Promoting Interoperability, and Improvement Activities, weighted under 42 CFR §414.1380. Reporting is voluntary for many small practices, so absence of a MIPS score is not a quality signal.

Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus continuous Maintenance of Certification cycles. Verify any individual provider's status through certificationmatters.org (ABMS) or osteopathic.org (AOA).

MATHEW CANNAVA, M.D. is a Dermatology Physician provider practicing in SOLDOTNA, Alaska, according to the CMS National Plan and Provider Enumeration System (NPPES). Credentials: M.D.. NPI: 1245368695. This profile includes practice location, specialty classification, and organizational affiliations from the CMS provider registry. Provider information is self-reported to CMS and updated monthly.

MATHEW CANNAVA, M.D. appears in the CMS NPPES registry as a Dermatology Physician provider holding M.D. credentials at 247 N FIREWEED ST, SOLDOTNA, AK, 99669, with a listed phone of (907) 262-7546. NPI 1245368695 was issued on 02/28/2007. Because NPPES data is self-reported by the provider and refreshed monthly, the address, phone, and specialty reflect what CANNAVA most recently submitted to CMS rather than a vetted directory listing, which is why patients should always confirm the practice is still at this location before scheduling.

Medicare Part D records for calendar year 2023 show 456 prescription claims written by this provider, covering 247 Medicare beneficiaries and totaling roughly $140K in drug spend, split 7% brand-name and 93% generic by claim count. These figures capture only Medicare Part D — commercial insurance, Medicaid, and cash-pay prescriptions are not included, and any drug-beneficiary cell under 11 is suppressed by CMS for patient privacy. On the CMS Merit-based Incentive Payment System, this provider earned a Final Score of 0/100 for the 2023 performance year (Quality 0), compared with the national average of 83.1.

Dermatology Physician is a mid-sized specialty nationwide, with 14,610 enrolled providers across 53 states and an average of 729 Part D claims per prescriber, so the context for interpreting these metrics differs meaningfully from a primary-care baseline. Important: PlainDoctor is a directory of publicly available government data, not medical advice, a malpractice database, or a quality rating. Inclusion here does not imply a recommendation, and absence of complaints or sanctions on this page does not mean none exist — always verify credentials through the NPPES NPI Registry, your state medical board, and the ABMS or AOA before making healthcare decisions.

Practice Address

247 N FIREWEED ST
SOLDOTNA, AK 99669

Provider Details

NPI 1245368695
Specialty Dermatology Physician
Credentials M.D.
Gender Male
NPI Issued 02/28/2007

CMS Quality Score (MIPS)

Merit-based Incentive Payment System (MIPS) scores from CMS, 2023 performance year.

0
Final Score
Avg: 83.1
0
Quality

Reporting: Individual

Brand vs generic prescribing mix · Generic-heavy

MATHEW CANNAVA, M.D. — brand share 7.0%
Specialty average (est.)

7% brand-name claims vs 93% generic, on 456 2023 Medicare Part D claims.

The federal Medicare Part D Generic Dispensing Rate national benchmark sits near 90% generic / 10% brand for primary-care prescribers, per CMS Office of the Actuary 2024 estimates. Higher brand share is common in specialty prescribing where generic equivalents are not available.

Medicare Part D Prescribing Data

CMS Medicare Part D prescriber-level data for calendar year 2023.

456
Total Claims
$140K
Total Drug Cost
247
Medicare Beneficiaries

Prescribing Breakdown

30-Day Fills
559
Total Day Supply
14,065
Brand vs Generic
7% brand / 93% generic
Brand Drug Cost
$121K
Generic Drug Cost
$19K
Antibiotic Claims
72

Patient Demographics

Average Patient Age
74.9 years
Avg HCC Risk Score
0.92
Gender Split
37% female / 63% male
Age Distribution
<65: 13, 65-74: 111, 75-84: 95, 85+: 28

Top Prescribed Drugs (Medicare Part D)

Top drugs by claim count for calendar year 2023. Based on Medicare Part D data only.

Drug Claims
Triamcinolone Acetonide
94
Imiquimod
50
Cephalexin
45
Clobetasol Propionate
34
Fluorouracil
34
Ketoconazole
23
Minocycline Hcl
22
Hydrocortisone
20
Humira
Adalimumab
13

* Counts below 11 are suppressed by CMS for patient privacy. Generic names shown where available from CMS Part D data.

Dermatology Physician Overview

How MATHEW CANNAVA, M.D. fits within the Dermatology Physician landscape nationally.

14,610
Dermatology Physician Providers in US
53
States with Dermatology Physician
729
Avg Claims per Provider

MATHEW CANNAVA, M.D.'s 456 claims are below the specialty average of 729.

Nearby Dermatology Physician Providers in Alaska

Other clinicians with the same primary specialty enrolled in Alaska, drawn from the same CMS NPPES roster as CANNAVA.

Compare Dermatology Physician nationally: see state-by-state distribution →

Frequently Asked Questions

What is MATHEW CANNAVA, M.D.'s specialty?
MATHEW CANNAVA, M.D. specializes in Dermatology Physician and practices in SOLDOTNA, Alaska. Credentials: M.D..
How much does MATHEW CANNAVA, M.D. prescribe under Medicare Part D?
In 2023, MATHEW CANNAVA, M.D. wrote 456 Medicare Part D claims totaling $140K in drug costs for 247 beneficiaries.
What is MATHEW CANNAVA, M.D.'s Medicare quality score?
MATHEW CANNAVA, M.D. has a CMS MIPS Final Score of 0/100 (Quality: 0). The national average MIPS Final Score is 83.1. Source: CMS Merit-based Incentive Payment System (MIPS) 2023.
Where is MATHEW CANNAVA, M.D. located?
MATHEW CANNAVA, M.D. is located at 247 N FIREWEED ST, SOLDOTNA, AK, 99669. Phone: (907) 262-7546.
What is MATHEW CANNAVA, M.D.'s NPI number?
MATHEW CANNAVA, M.D.'s National Provider Identifier (NPI) is 1245368695, issued on 02/28/2007.
Does MATHEW CANNAVA, M.D. prescribe more brand-name or generic drugs?
MATHEW CANNAVA, M.D.'s prescribing is 7% brand-name and 93% generic drugs by claim count, with $121K in brand drug costs.
How many Dermatology Physician providers are there in the US?
There are 14,610 Dermatology Physician providers across 53 states in the US. The average Dermatology Physician provider writes 729 Medicare Part D claims per year.
What drugs does MATHEW CANNAVA, M.D. prescribe most often?
Based on 2023 Medicare Part D data, MATHEW CANNAVA, M.D.'s most frequently prescribed drugs include Triamcinolone Acetonide, Imiquimod, Cephalexin. This reflects Medicare Part D prescriptions only and does not include commercial insurance or other payer types.
Does MATHEW CANNAVA, M.D. accept Medicare?
MATHEW CANNAVA, M.D. appears in CMS Medicare data with 456 Part D claims and 247 Medicare beneficiaries in 2023. Contact the provider's office directly to confirm current Medicare enrollment and accepted plans.
How can I verify MATHEW CANNAVA, M.D.'s credentials?
MATHEW CANNAVA, M.D.'s NPI is 1245368695 with credentials M.D.. You can verify this through the NPPES NPI Registry, check state medical board records, and confirm board certification through the ABMS or AOA.

Data Sources

Provider Directory
CMS National Plan and Provider Enumeration System (NPPES), download.cms.gov/nppes, updated monthly. Contains NPI, specialty, credentials, and practice location.
Specialty Classification
NUCC Health Care Provider Taxonomy (nucc.org), the industry standard for classifying provider specialties in Medicare and Medicaid billing.
Prescribing Data
CMS Medicare Part D Prescriber Public Use File (2023). Includes claims, drug costs, beneficiaries, and opioid prescribing rates.
Quality Performance
CMS Merit-based Incentive Payment System (MIPS) — 2023 performance year.
Limitations
Provider data is self-reported to CMS. Prescribing data reflects Medicare Part D only and does not include commercial insurance, Medicaid, or cash prescriptions. Claims below 11 beneficiaries are suppressed by CMS for privacy.

See our complete data methodology for details on how we collect and process government data.

Data as of April 2026 (NPPES) / 2023 (Medicare Part D). Source: Centers for Medicare & Medicaid Services (CMS).

Disclaimer: Data from CMS NPPES and Medicare Part D. PlainDoctor does not rate or rank providers. Provider information is self-reported and may not be current. Always verify information directly with the provider. About · Methodology